康諾亞漲近9%，治療皮炎新藥臨牀實驗成功達到主要研究終點

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

康諾亞漲近9%，治療皮炎新藥臨牀實驗成功達到主要研究終點

uSMART盈立智投 05-30 09:45

截至發稿，康諾亞-B漲8.83%。根據該公司公告，其自主研發的1類新藥CM310重組人源化單克隆抗體注射液治療中重度特應性皮炎(AD)的III期確證性臨牀研究(試驗方案編號：CM310AD005)已完成揭盲及初步統計分析，主要研究終點均成功達到。

康诺亚-B(02162.HK)

Relevant Stocks

康诺亚-B(02162.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

康諾亞漲近9%，治療皮炎新藥臨牀實驗成功達到主要研究終點

Services

About Us

Agreement Statement